Biosimilar Interchangeable Exclusivity Guidance Still Planned Despite Memo Release, US FDA Says

While many interpretations of the law protecting the first interchangeable biosimilar approved for a reference product are included in a recently released FDA memo, the agency says it has a limited scope.